Related Experiment Video

Updated: Jul 3, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

Jinhai Wang1, Jay Lozier, Gibbes Johnson

  • 1Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, NIH Building 29B, 8800 Rockville Pike, Bethesda, Maryland 20892, USA.

Nature Biotechnology
|August 9, 2008
PubMed

Insights

Lysosomal storage diseases require enzyme replacement therapy, but immune responses can reduce effectiveness. Understanding antibody development is key to improving treatment outcomes and patient safety.

Area of Science:

  • Biochemistry
  • Immunology
  • Genetics

Background:

  • Lysosomal storage diseases (LSDs) stem from deficient lysosomal enzymes, leading to substrate accumulation and cell death.
  • Enzyme replacement therapy (ERT) is a primary treatment for LSDs, but immune responses frequently complicate treatment.
  • Adverse immune reactions to ERT can neutralize enzyme activity, diminishing therapeutic efficacy and causing severe side effects.

Purpose of the Study:

  • To investigate the intricate links between genetic mutations in LSDs and the resulting clinical outcomes.
  • To explore the role of endogenous residual enzyme proteins (cross-reactive immunologic material) in immune responses.
  • To understand the development of neutralizing antibodies and their impact on ERT effectiveness and patient prognosis.

Main Methods:

  • Analysis of genetic mutations associated with LSDs.
  • Assessment of cross-reactive immunologic material (CRIM) levels.
  • Monitoring of neutralizing antibody development in patients undergoing ERT.
  • Correlation of immunological findings with clinical outcomes.

Main Results:

  • Demonstrated a significant correlation between specific genetic mutations and the presence of CRIM.
  • Identified patterns in neutralizing antibody development influenced by CRIM status.
  • Showcased the direct impact of antibody formation on ERT efficacy and disease progression.

Conclusions:

  • Understanding the interplay between genetic mutations, CRIM, and antibody responses is critical for managing LSDs.
  • Developing strategies to induce immune tolerance is essential for mitigating life-threatening responses to ERT.
  • Personalized treatment approaches considering immune profiles can improve outcomes for LSD patients.

More Related Videos

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Concept Videos

Antidotes01:17

Antidotes

Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Cross-reactivity00:42

Cross-reactivity

Overview
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...